



Attorney Docket No. C1041/7002 (AWS)

1635
Box 84

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wagner et al.
Serial No.: 09/241,653
Filed: February 2, 1999
For: METHODS FOR REGULATING HEMATOPOIESIS USING CpG-
OLIGONUCLEOTIDES
Examiner: J. Zara
Art Unit: 1635

RECEIVED

OCT 22 2001

TECH CENTER 1600/2900

#23

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 12th day of October, 2001.

Alan W. Steele

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

- ☒ Amendment
- ☒ Appendix to Amendment
- ☒ Statement Pursuant to 37 C.F.R. 1.821(f)
- ☒ Substitute Sequence Listing
- ☒ Computer Readable Diskette
- ☒ Copy of Notice to Comply with Requirements for Sequence Disclosures
- ☒ Return Receipt Postcard


If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617)720-3500, Boston, Massachusetts.

If any fee is required, then please charge the fee to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

Alan W. Steele, Reg. No. 45,128
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500
Facsimile (617) 720-2441

Docket No. C1041/7002 (AWS)
October 12, 2001



#23/R.T. 10/24
Attorney Docket No. C1041/7002 (AWS)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wagner et al.
Serial No: 09/241,653
Filed: February 2, 1999
For: METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
Examiner: J. Zara
Art Unit: 1635

RECEIVED
OCT 22 2001
TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 12th day of October, 2001.

Alan W. Steele

Commissioner for Patents
Washington, D.C. 20231

AMENDMENT

In response to the Office Action dated September 12, 2001, please amend the application as follows.

In the Specification

Please enter the enclosed substitute Sequence Listing into the specification.

Please replace the following paragraphs with the clean form replacement paragraphs as directed below. Marked up versions of the replacement paragraphs showing all the changes relative to the previous version of the paragraphs are provided separately as an Appendix.

- (1) On page 6-7, replace the paragraph beginning at line 17 on page 6 with the following:

Cytokine production and hematopoiesis

D¹
As described above the cytokine repertoire induced by CpG-ODN injection is Th1 in nature, and ample evidence suggests this exerts a strong Th1 biasing effect to the subsequent immune response development. Zhao et al. administered to mice a 27-mer phosphorothioate oligonucleotide (sequence 5'-TCG TCG CTG TCT CCG CTT CTT CTT GCC-3'; SEQ ID